ATE474917T1 - Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide - Google Patents
Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptideInfo
- Publication number
- ATE474917T1 ATE474917T1 AT07723889T AT07723889T ATE474917T1 AT E474917 T1 ATE474917 T1 AT E474917T1 AT 07723889 T AT07723889 T AT 07723889T AT 07723889 T AT07723889 T AT 07723889T AT E474917 T1 ATE474917 T1 AT E474917T1
- Authority
- AT
- Austria
- Prior art keywords
- therapeutic polypeptides
- increase
- vivo recovery
- polypeptides
- recovery
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 238000011084 recovery Methods 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06007552 | 2006-04-11 | ||
| PCT/EP2007/002948 WO2007115724A2 (de) | 2006-04-11 | 2007-04-02 | Method of increasing the in vivo recovery of therapeutic polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE474917T1 true ATE474917T1 (de) | 2010-08-15 |
Family
ID=36778259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07723889T ATE474917T1 (de) | 2006-04-11 | 2007-04-02 | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100222554A1 (de) |
| EP (2) | EP2263696A1 (de) |
| JP (1) | JP2009533364A (de) |
| KR (1) | KR101492422B1 (de) |
| AT (1) | ATE474917T1 (de) |
| AU (1) | AU2007236280B2 (de) |
| CA (1) | CA2649199C (de) |
| DE (1) | DE602007007923D1 (de) |
| DK (1) | DK2007885T3 (de) |
| ES (1) | ES2349024T3 (de) |
| PL (1) | PL2007885T3 (de) |
| WO (1) | WO2007115724A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1816201A1 (de) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| WO2009051717A2 (en) * | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
| US20120148557A1 (en) * | 2009-08-20 | 2012-06-14 | Ulrich Kronthaler | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| MX356527B (es) | 2010-07-09 | 2018-06-01 | Bioverativ Therapeutics Inc | Polipeptidos de factor ix y metodos para usarlos. |
| EP3461905B1 (de) * | 2010-11-22 | 2020-08-05 | Amicus Therapeutics, Inc. | Neuartige signalsequenzen zur verbesserung der proteinexpression und der abscheidung rekombinanter enzyme und anderer proteine |
| WO2014052490A1 (en) * | 2012-09-25 | 2014-04-03 | Biogen Idec Ma Inc. | Methods of using fix polypeptides |
| SG10201707600XA (en) | 2013-03-15 | 2017-11-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| CN113631182A (zh) | 2018-10-10 | 2021-11-09 | 阿米库斯治疗学公司 | 二硫键稳定的多肽组合物和使用方法 |
| CN113164560A (zh) * | 2018-10-26 | 2021-07-23 | Vrije布鲁塞尔大学 | 改善基因疗法的新工具及其用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US5364771A (en) * | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| WO1996018412A1 (en) * | 1994-12-12 | 1996-06-20 | Beth Israel Hospital Association | Chimeric cytokines and uses thereof |
| DE19538715A1 (de) | 1995-10-18 | 1997-04-30 | Behringwerke Ag | Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII |
| JP3735921B2 (ja) * | 1996-02-07 | 2006-01-18 | 三菱ウェルファーマ株式会社 | ＧＰＩｂ・脂質複合体およびその用途 |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| DK1088084T3 (da) * | 1998-06-15 | 2007-01-29 | Gtc Biotherapeutics Inc | Erythropoietin analog-humant serumalbumin fusionsprotein |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US20040010134A1 (en) * | 2000-04-12 | 2004-01-15 | Rosen Craig A. | Albumin fusion proteins |
| PL206148B1 (pl) * | 2000-02-11 | 2010-07-30 | Bayer HealthCare LLCBayer HealthCare LLC | Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego |
| IL154879A0 (en) * | 2000-10-02 | 2003-10-31 | Novo Nordisk As | Factor vii glycoforms |
| WO2002032461A2 (en) * | 2000-10-18 | 2002-04-25 | Maxygen Aps | Protein c or activated protein c-like molecules |
| EP1444986A1 (de) * | 2003-02-07 | 2004-08-11 | Aventis Behring GmbH | Pharmazeutische Zusammensetzung zur verbesserten Behandlung von Krankheiten mit verminderter Blutgerinnung |
| TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US20080305518A1 (en) * | 2004-05-04 | 2008-12-11 | Novo Nordisk Healthcare A/G | O-Linked Glycoforms Of Polypeptides And Method To Manufacture Them |
| EP1816201A1 (de) * | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät |
| EP1867660A1 (de) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Fusionsprotein welches proteolytisch geschnitten werden kann und einen Faktor der Blutgerinnungskaskade enthält |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| AU2007338298B2 (en) * | 2006-12-22 | 2013-02-07 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
-
2007
- 2007-04-02 KR KR20087027542A patent/KR101492422B1/ko active IP Right Grant
- 2007-04-02 DE DE602007007923T patent/DE602007007923D1/de active Active
- 2007-04-02 WO PCT/EP2007/002948 patent/WO2007115724A2/de active Application Filing
- 2007-04-02 ES ES07723889T patent/ES2349024T3/es active Active
- 2007-04-02 JP JP2009504607A patent/JP2009533364A/ja active Pending
- 2007-04-02 DK DK07723889.7T patent/DK2007885T3/da active
- 2007-04-02 EP EP10168156A patent/EP2263696A1/de not_active Withdrawn
- 2007-04-02 AT AT07723889T patent/ATE474917T1/de active
- 2007-04-02 EP EP07723889A patent/EP2007885B1/de active Active
- 2007-04-02 US US12/226,188 patent/US20100222554A1/en not_active Abandoned
- 2007-04-02 PL PL07723889T patent/PL2007885T3/pl unknown
- 2007-04-02 CA CA2649199A patent/CA2649199C/en not_active Expired - Fee Related
- 2007-04-02 AU AU2007236280A patent/AU2007236280B2/en not_active Ceased
-
2013
- 2013-06-19 US US13/921,815 patent/US20130337532A1/en not_active Abandoned
-
2014
- 2014-03-27 US US14/227,397 patent/US20140248686A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2349024T3 (es) | 2010-12-21 |
| EP2007885A2 (de) | 2008-12-31 |
| WO2007115724A2 (de) | 2007-10-18 |
| DK2007885T3 (da) | 2010-11-08 |
| PL2007885T3 (pl) | 2010-12-31 |
| CA2649199C (en) | 2015-01-20 |
| CA2649199A1 (en) | 2007-10-18 |
| EP2007885B1 (de) | 2010-07-21 |
| KR20090008329A (ko) | 2009-01-21 |
| US20100222554A1 (en) | 2010-09-02 |
| JP2009533364A (ja) | 2009-09-17 |
| WO2007115724A3 (de) | 2008-03-20 |
| KR101492422B1 (ko) | 2015-02-12 |
| AU2007236280A1 (en) | 2007-10-18 |
| DE602007007923D1 (de) | 2010-09-02 |
| EP2263696A1 (de) | 2010-12-22 |
| US20140248686A1 (en) | 2014-09-04 |
| AU2007236280B2 (en) | 2013-07-25 |
| US20130337532A1 (en) | 2013-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE474917T1 (de) | Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide | |
| CL2009001258A1 (es) | Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina. | |
| GT200700059A (es) | Proteinas de fusion de exendina | |
| MX2008002101A (es) | Fusiones de la proteina-1 quimiotactica de monocito. | |
| AR060862A1 (es) | Proteinas de fusion rage, formulaciones y metodos de uso de estas | |
| CY1121049T1 (el) | Καινοτομες αλληλουχιες σηματος για τη βελτιωση των πρωτεϊνικων εκφρασεων και της εκκρισης των ανασυνδυασμενων ενζυμων και αλλων πρωτεϊνων | |
| HRP20220214T1 (hr) | Imunomodulacijska sredstva | |
| NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
| ATE426174T1 (de) | Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| WO2013075066A3 (en) | Variant serum albumin with improved half -life and other properties | |
| WO2010117760A3 (en) | Fusion proteins comprising canine fc portions | |
| ATE527345T1 (de) | Chimäres fusionsprotein mit überlegenen chaperon- und faltungsaktivitäten | |
| EA201290722A1 (ru) | Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение | |
| CY1117697T1 (el) | Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii | |
| IL220164B (en) | A method for purifying a purified antibody, antibody fragment, or fc-fused protein using an affinity chromatography matrix | |
| WO2008114149A3 (en) | Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains | |
| ECSP12011577A (es) | Produccion recombinante de péptidos | |
| MX2014000054A (es) | Moleculas de union anti-alfa sinucleina. | |
| HK1125387A1 (en) | Compositions and methods for fusion protein separation | |
| EP2035572A4 (de) | Verfahren zur herstellung von faktor-viii-proteinen durch rekombinationsverfahren | |
| NO20084776L (no) | En fremgangsmåte for konsentrasjon av et polypeptid | |
| DE602006015421D1 (de) | HER-2/neu Multipeptidimpfstoff | |
| WO2010023670A3 (en) | Methods for covalently attaching a polymer to a methionine residue in proteins and peptides | |
| MX2016008355A (es) | Anticuerpos que comprenden extensiones de polipeptidos de cadena ligera en el extremo c y conjugados y metodos de uso de estos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2007885 Country of ref document: EP |